Intramyocardial Injection for the Study of Cardiac Lymphatic Function in Zebrafish

Laila Abd Elmagid; Nishant Mittal; Isaac Bakis; Ching-Ling Lien; Michael R. Harrison

doi:10.3791/64504

JoVE Journal > Developmental Biology

Developmental Biology

Intramyocardial Injection for the Study of Cardiac Lymphatic Function in Zebrafish

Published: September 20, 2022

doi:

10.3791/64504

Laila Abd Elmagid*^1,2, Nishant Mittal*^1,2, Isaac Bakis^1,2, Ching-Ling Lien³, Michael R. Harrison^1,2

¹Cardiovascular Research Institute,Weill Cornell Medicine, ²Department of Cell and Developmental Biology,Weill Cornell Medicine, ³The Saban Research Institute and Heart Institute,Children’s Hospital Los Angeles

Summary

The present protocol allows efficient and stable delivery of fluorescent microspheres (MS) and quantum dots (QD) into the myocardium of live fish that can be tracked (traced) over time.

Abstract

Zebrafish have proved to be an important model for studying cardiovascular formation and function during postembryonic development and regeneration. The present protocol describes a method for injecting fluorescent tracers into the zebrafish myocardium to study interstitial fluid and debris uptake into cardiac lymphatic vessels. To do so, microspheres (200 nm diameter) and quantum dots (<10 nm diameter) are introduced into the myocardium of live zebrafish, which can be tracked using ex vivo confocal microscopy. These tracers are then tracked intermittently over several hours to follow clearance from the myocardium into cardiac lymphatic vessels. Quantum dots are transported through cardiac lymphatic vessels away from the heart, while larger microspheres remain at the injection site for over three weeks. This method of intramyocardial injection can be extended to other uses, including the injection of encapsulated MS or hydrogels to locally release cells, proteins, or compounds of interest to a targeted region of the heart.

Introduction

The lymphatic system is essential for maintaining tissue-fluid balance, modulation of the immune response following injury, and absorption of lipids in the gut¹. Accumulating evidence supports the broad roles of the lymphatic system in various disease and developmental contexts. However, mechanistic studies are hampered because lymphatic vessels can be hard to visualize, and their functionality can be uncertain. Early imaging techniques relied on the natural ability of the lymphatic system to interstitially absorb injected tracers, and then transport them through the lymphatic vessel network, allowing detection and visualization¹. Not only can this method be used to visualize the lymphatics, but it can also be used to quantify their ability to uptake fluid and macromolecules from the tissue.

The vast lymphatic network also encompasses the cardiac lymphatic system, which has been shown to play an integral role in zebrafish regeneration²^,³^,⁴. Understanding the differences and similarities in lymphatic function across different species is crucial to utilizing this knowledge clinically. Therefore, there is a need to explore the technologies that can measure and visualize lymphatic function across different model organisms⁵^,⁶. Lymphatics are blunt-end vessels that transport fluid in one direction, away from the tissue⁷. Intramyocardial injection of fluorescent dyes is required to observe lymphatic drainage from cardiac tissue. Intramyocardial injections have also been used clinically and in pre-clinical mammalian models to transplant stem and progenitor cells or exogenous compounds such as hydrogel to test for the improvement of heart function after myocardial infarction⁸^,⁹^,¹⁰. Zebrafish intramyocardial injection has not been described in detail, which has limited the use of such experimental approaches to the zebrafish heart.

Injections into the zebrafish's pericardial space and the systemic blood flow within the lumen of the heart have been described in detail previously¹¹^,¹², and successful intramyocardial injection of fluorescent tracers in adult zebrafish has been reported². The present article provides a detailed protocol for carrying out intramyocardial injections in adult zebrafish. Several transgenic zebrafish lines can identify lymphatic vessels; however, there is a need to explore approaches to understanding lymphatic drainage or to visualize lymphatics in the absence of transgenic markers. Fluorescent tracers, microspheres (MS), and quantum dots (QD) are used here to visualize the injection site and fluid flow into the cardiac lymphatics. QD are fluorescent nanocrystals of <10 nm in diameter whose optical properties can be tuned and adapted to serve many biomedical applications¹³^,¹⁴. QD are readily taken up by lymphatic vessels but not by blood vasculature when injected interstitially¹⁵^,¹⁶. MS are fluorescently coated polystyrene beads of approximately 200 nm in diameter¹⁵. As such, MS are considerably larger than QD and significantly more persistent when injected into the myocardium, allowing consistent identification of the injection site. This method is useful to study lymphatic function during cardiac regeneration but can be adapted to study various aspects of cardiac biology using the stable localized introduction of coated beads, hydrogels, or cell preparations.

Protocol

All animal procedures were approved by the Institutional Animal Care and Use Committee at Weill Cornell Medicine (protocol 2020-0027) and followed proper guidelines. The following experiments were performed with male and female AB wild-type zebrafish aged 14-to-20-months post fertilization for adults, and 35-days post fertilization for juveniles.

1. Needle pulling and reagent preparation

Pull a 1.2 mm OD (outer diameter) standard borosilicate glass capillary using a needle puller (Figure 1A,B) (see Table of Materials), into two needles using optimal settings. In this case, heat 525; pull 65; velocity 60; time 250.
Vortex commercially obtained stock colloidal solutions of MS (1% solids in water) and QD (2 µM, see Table of Materials).
NOTE: The MS colloidal solution is white in color and easily seen when injected.
Filter 500 µL of MS stock colloidal solution through a 0.45 µm syringe filter (see Table of Materials) to minimize clogging the needle.
To prepare the working colloidal solution of only MS, dilute 100 µL of the filtered MS colloidal solution with 100 µL of 1x PBS (Phosphate buffered saline).
To prepare the working colloidal solution of MS and QD, mix 100 µL of the filtered MS colloidal solution with 100 µL of the QD colloidal solution.
NOTE: Depending on the experiment, MS, and QD can be mixed or injected individually.
Prepare and arrange the necessary reagents and equipment: stereoscope, wet sponge, micromanipulator, injector, 20 µL pipette, tricaine solution, straight iridectomy scissors, forceps, pulled needles, microloader femtotips, recovery tanks, and nets as shown in Figure 1D (see Table of Materials).
Turn on the injector air supply and set up the gated injection pulse rather than the timed injection pulse.
NOTE: For the instrumental details, please see Table of Materials. Some instruments require the injection pedal to be inserted into the gated input port on the instrument's back side.

2. Injection station preparation and zebrafish preparation

Turn on the dissecting microscope and adjust the focus.
With microloader pipette tips, load the control solution (e.g., 0.05% phenol red in 1x PBS).
Insert the needle into the needle holder of the microinjector.
Under the dissecting microscope, cut the pulled needle at 1 mm from the tip using forceps.
NOTE: Cutting the needle as narrow as possible is optimal for piercing the myocardium. However, if the needle is too narrow, it may bend when trying to penetrate the cardiac tissue.
Set the appropriate injection pressure to around 0.50 kPa/7.3 psi, and the balance pressure to around 0 psi so there is no liquid retraction into the needle (Figure 1C).
Once the desired pressure is reached, test the injection setup, and record the time taken to inject a bolus of solution into mineral oil that is less than 1 mm in diameter (<0.5 µL).
NOTE: Ideally, the injection must release the fluid at approximately 50 nL/s to give an approximate bolus diameter of 0.8 mm in 5 s. Depending on the tip diameter of the needle, adjustments in time and pressure can be made to inject 0.25-0.3 µL into a single fish over a 5 s injection. Higher injection pressure, as opposed to a longer injection time, is desirable to ensure that the high interstitial tissue pressure can be overcome during the injection.
Load the needle with the selected volume (e.g., 10-15 µL, Figure 1B) of injection solution and repeat steps 2.5-2.6.
NOTE: Gated injections will allow one to inject for as long as the foot pedal is pressed, allowing for adjustments of the tip position to be made until the right intratissue injection site is found.
Insert the needle loaded with injection solution into the needle holder of the microinjector.

3. Injection

Prepare a grooved sponge by carving a fish-like outline in the middle.
Prepare the working concentration of tricaine by diluting 4.2 mL of stock solution (4 mg/mL) into 100 mL of fish facility water (see Table of Materials) in a crystallizing dish.
Anesthetize the zebrafish in tricaine solution until the movement of the gills is reduced and it has stopped swimming.
NOTE: Pinch the tail to confirm the loss of response in anesthetized zebrafish.
Position the zebrafish with its ventral side facing the objective lens in the moistened grooved sponge under the dissecting microscope (Figure 2A and Figure 3A).
Use iridectomy scissors to make a small transverse cut at the level of the pectoral fins and open the chest cavity (Supplementary Video 1).
With forceps, gently peel away the pericardium to expose the apex of the heart (Figure 3B).
With the loaded needle holder in hand, direct the needle toward the apex of the ventricle at an acute angle of <30° to the body axis.
Insert a 0.1-0.2 mm needle into the heart without penetrating too deep into the ventricle (Figure 2B and Figure 3B).
NOTE: If the tip end of the needle fills with blood, retract the needle slightly to avoid injecting the MS and QD into the ventricular lumen.
With the needle inserted into the heart apex, slightly raise the ventricle away from the body by reducing the angle between the needle and the body axis while moving the needle tip toward the base of the heart (Figure 2C and Figure 3C).
NOTE: The needle may be faintly visible through the myocardial wall.
Push the needle further toward the head so the needle tip moves toward the myocardium surface.
Inject by pressing the pedal of the microinjection device for ~1-5 s or until a white spot is visible within the heart tissue (Figures 2C and Figure 3C,D).
If the chest cavity starts filling with injection fluid while injecting, it indicates that the needle tip has completely penetrated the myocardium (Figure 2D). Withdraw the needle slowly until a buildup of microbeads is visible within the tissue.
Reposition the needle tip if the fluid is injected into the ventricular lumen and cleared with the subsequent heartbeat (Figure 2E). In such a situation, lift the tip of the needle and push the needle toward the direction of the head until the injection pressure results in a white spot in the tissue.
If no white fluid or spot is visible, then the injection needle is blocked. In such a situation, retract the needle fully. To continue the experiment, either slightly break the tip of the needle or replace the needle. In both cases, check the injection flow prior to reinjecting the myocardium.
After successful injection, gently withdraw the needle from the myocardium (Figure 3F) and immediately transfer the zebrafish into a recovery tank with fish facility water.
Monitor the fish until it totally recovers from the tricaine.
Transfer the recovered fishes into a 2.8 L tank and place it in the fish facility, until the desired time point for heart extraction.

4. Heart extraction and imaging

Prepare the working concentration of tricaine by diluting 4.2 mL of stock solution (4 mg/mL) into 100 mL of fish facility water in a crystallizing dish.
Terminally anesthetize the zebrafish in tricaine solution until the movement of the gills has stopped and it is unresponsive.
Transfer the zebrafish to a moistened grooved sponge under the dissecting microscope positioned ventral side facing the objective lens.
Open the ventral wall of the chest with iridectomy scissors at the level of the pectoral fins.
Open the pericardial sac and locate the outflow track of the heart. Use forceps to grasp the aorta anterior to the Bulbous Arteriosus (BA) and carefully pull them up with the base of the ventricle.
With the anterior pole of the heart raised, cut the ventral aorta/sinus venosus to release the heart and place in a 35 mm Petri dish containing PBS.
Using forceps, remove any blood clots and fix the heart in 4% PFA (wt/vol) for 15 min.
Image the hearts using a microscope capable of acquiring the fluorescent wavelengths used.
NOTE: In the example date, a confocal microscope with 405, 488, 567, and 647 laser lines was used.
Use ImageJ/Fiji software (see Table of Materials) for image analysis.
NOTE: Calculation of QD or MS enrichment was performed using the high or low thresholding and create selection functions with the lymphatic vessel channel to first select regions of lymphatic vessels and those lacking vessel signal. Then, the Measure function was used to measure pixel intensity of the QD or MS channel from which a ratio of the two selections were calculated.

Representative Results

Immediately after injection, a small white region of the myocardial wall must be visible (Figure 3F). This region will show bright fluorescent labeling of the injected MS and QD (Figure 4B,E). In addition, there may be weak and sporadic fluorescence puncta on the heart's outer surface from any QD and MS in the pericardial space following the procedure (Figure 4B,E). The injected tracers can be tracked over time. To do this, the fish needs to be euthanized and hearts collected and placed under a confocal microscope as previously described¹⁶.

MS are still observed at the injection site 1 day after injection, with some trapped on the outer surface of the atrium and bulbous arteriosus (BA) (Figure 4B). MS are stable in the myocardium for over 3 weeks (Figure 4C,D) suggesting they could be used to introduce exogenous compounds or cells (Supplementary Figure 1).

In contrast to the MS (200 nm diameter), smaller QD (<10 nm diameter) are more transiently located at the injection site. After 1 h post-injection (hpi) both MS and QD were found at the injection site (Figure 4E). Over the time frame of 12-24 h, the smaller QD were more dispersed than MS from the injection site as well as more concentrated within the lymphatic endothelium, including the lymphatic vasculature on the BA (Figure 4F,G; Figure 4I–K). The larger MS remained at the injection site, suggesting that the smaller QD become dispersed with the interstitial fluid, and then taken up with this fluid into the lymphatic vessels. The increased concentration of fluorescence signal in the QD channel is observed to overlap with lymphatic transgenic fluorescence (Figure 4G,H), which can be used to follow lymphatic uptake (Figure 4K).

After testing the lymphatic clearance of the interstitial fluid and macromolecules, this assay can be applied to investigate delayed clearance with underdeveloped or enhanced lymphatic function. To demonstrate this, QD was injected into juvenile zebrafish (35 dpf) that lack functional cardiac lymphatic vessels and observed no uptake of QD (Figure 4H).

Given the stability of the injected MS (Figure 4C,D) we decided to investigate the use of this method to deliver exogenous compounds. To do this, MS were soaked overnight in 10 mM solution of 4-hydroxytamoxifen (4OHT) prior to injection into transgenic zebrafish. Transgenic zebrafish injected with 4OHT showed localized CreERt2 activity in the ventricle (Supplementary Figure 1) suggesting such an approach is possible with suitable MS preparation or use of encapsulated MS as applicable.

Figure 1: Apparatus setup for intramyocardial injection. (A) Needle puller. (B) A pulled needle with injection fluid. (C) A close-up view of the injector settings. (D) General set up of injection station. 1) Stereoscope connected to needle holder and manipulator. 2) Wet sponge placed over a 90 mm dish to hold anesthetized adult zebrafish. 3) Micromanipulator to hold needle in-between injections (note, injections are performed freehand). 4) Injector device. 5) 20 uL pipette. 6) Tricaine solution. 7) Solution of QD and MS. 8) Straight iridectomy scissor. 9) Pair of forceps.10) Pulled needles. 11) Microloader femtotips. 12) Recovery tanks. 13) Nets. Please click here to view a larger version of this figure.

Figure 2: Schematic representation of injection. The needle is introduced to the thorax through an opening in the chest (A), and then inserted into the heart at the apex (B). The needle tip is lifted and moved toward the head to inject within the ventral side of the myocardium; the asterisk indicates the puncture site, while the concentrated white mass indicates the injection site (C). The tip must not be far enough to be positioned within the lumen (D) or pushed too far anteriorly back through into the pericardial space (E), resulting in defuse and transient release of injection fluid. V, ventricle; A, atrium. Please click here to view a larger version of this figure.

Figure 3: Intramyocardial injection of adult fish. (A) Placement of an anesthetized zebrafish with the ventral side facing up. (B) Placement of the needle into the apex (arrowhead) of the ventricle. Insertion of the needle into the myocardium with the anterior movement of the tip within the cardiac ventricle at an angle of 30° or lower (C). Injection of QD and MS solution into interstitial space in the myocardial layer to form a small white mass (white arrowhead, D, and E). A white dot of the injection mix remains visible in the myocardium after needle removal (white arrowhead, F). Please click here to view a larger version of this figure.

Figure 4: Intramyocardial injection to study the function of the cardiac lymphatic vasculature. Whole-mount confocal imaging of intramyocardial injected adult non-transgenic wildtype (A–D) and transgenic zebrafish hearts expressing the pan-endothelial marker fli1a:GFP (green, E–G) and lymphatic endothelial marker prox1:Gal4-UAS:RFP (red in E–H) or flt4:mCitrine (red in I). The uninjected control hearts (A) lack intense fluorescence but have autofluorescence in the Bulbous Arteriosus (BA) and Epicardial Adipose Tissue (EAT). Intramyocardial injection of 200 nm MS (cyan) results in persistent and localized fluorescence at the injection site (cyan arrowheads) at 1 (B), 6 (C), and 21 dpi (D). Combined intramyocardial injection of MS (200 nm, cyan) and QD (10 nm, magenta) results in both being deposited at the injection site (E–H, cyan arrowheads). (E) At 1 h post-injection (hpi), MS remain at the injection site, QD are more dispersed but not strongly enriched in the lymphatic vessels on the BA (inset, red arrowhead; adult, 14 mpf/36 mm). (F) At 12 hpi, QD are randomly distributed throughout the ventricular chamber and outflow tract (adult, 16 mpf/29 mm). Also, QD are partially drained into lymphatic vessels on the BA overlapping with the prox1:Gal4-UAS:RFP positive signal (red and magenta arrowheads). (G) At 24 hpi, QD are highly concentrated within the lymphatic vessels on the BA overlapping with the prox1:Gal4-UAS:RFP positive signal (red and magenta arrowheads; adult, 19 mpf/34 mm). (H) At 24 hpi in Juveniles lacking cardiac functional lymphatic vessels (red arrowhead), QD are concentrated at the injection site (cyan arrowhead), with some diffuse QD found over the BA and ventricular chamber as observed in adult (Juvenile, 1 mpf/10 mm). (I) Example confocal image of the BA with flt4:mCitrine-labeled lymphatic vessels (red) and QD (gray) intramyocardially injected into the ventricle 24 h previously (adult, 19 mpf/34 mm). The yellow line denotes the plane of pixel intensity for which the histogram is shown (J). (K) Quantification of QD channel intensity inside flt4:mCitrine/prox1:Gal4-UAS:RFP-positive vessels on the BA normalized to that outside of the vessels on the same BA. QD intensity becomes increasingly enriched within the vessels after injection whereas the intensity of MS remains unenriched (mean, with SEM, n = 4-7 per timepoint). Scale bars: 200 µm (A–I) and 50 µm (insets, E–G). Abbreviation: BA = Bulbus Arteriosus, EAT = Epicardial Adipose Tissue, V = Ventricle, A = Atrium, MS = Microspheres, QD = Quantum dots, mpf = months post fertilization, mm = standard zebrafish length in millimeters. Please click here to view a larger version of this figure.

Supplementary Figure 1: Intramyocardial injection of the 4OHT soaked MS. (A) Schematic representation of cmlc2:CreERT2 expression construct used to generate transgenic zebrafish capable of induced expression of mCherry (and a dominant negative form of Gata4, dnGata4) in the cmlc2-positive cardiomyocytes when 4OHT is present¹⁷. (B) Expression of mCherry (red) in a zebrafish heart 14 days post induction (Juvenile; 35 dpf; 13.5 mm). 10 mM stock solution of 4OHT is diluted in system water to a final concentration of 10 µM into which zebrafish are immersed for 6 h. (C,D) Expression of mCherry (C; red) in zebrafish heart 3 days post intramyocardial injection of 4OHT soaked MS (D; Blue) in adult zebrafish (190 dpf; 24.5 mm). Scale bars: 50 µm (B) and 100 µm (C,D). Please click here to download this File.

Supplementary Video 1: Representative video to demonstrate the successful intramyocardial microinjection of QD + MS. Please click here to download this File.

Discussion

The present article has described a method to introduce exogenous material into the myocardium of zebrafish. This technique was developed to introduce QD and MS into the myocardium to study lymphatic function in homeostasis and regeneration²^,¹⁸. A similar approach has also been used to introduce QD into the myocardium of mice to investigate the presence and function of lymphatics after myocardial infarction¹⁹^,²⁰.

The penetration and positioning of the needle tip in the myocardium is a critical step of this procedure. The glass capillary needs to be sufficiently sharp to penetrate the dense myocardial tissue and rigid enough to not bend under the force of lifting the heart when positioning the injection site. The optimal balance between these two tip properties can be achieved by varying how much the tip size is reduced with forceps. An acute injection angle is best for forcing the tip through the myocardium wall. Injection at the selected site is challenging due to the beating movement of the heart. Therefore, the injection must be carried out in a controlled fashion by first resting the tip on the beating heart and moving it slightly to adjust the injection site. Some further adjustment of the injection angle must be made as the tip contacts the beating heart to keep the two perpendicular when finally applying enough force to puncture the myocardium.

Once in the heart tissue, the tip position is manipulated by raising the apex of the heart with the needle and then continuing to extend the tip. Failure to do so will result in luminal injection into the circulation. With further pressure applied toward the anterior of the fish, the needle is often visible in the tissue as it re-enters or continues to move toward the base of the myocardium. At this point, a short pulse of injection pressure will indicate the exact tip position and if it is in the desired injection location. The final amount of injected material will affect the duration of time it resides within the tissue. Larger amounts will take longer to clear, and QD will be visible in the lymphatics for longer. The time taken for visible uptake to start is also a function of the relative distance between the injection site and the cardiac lymphatic vessels. Injected material proximal to the lymphatic vessels will be taken up sooner than the material further away. As the lymphatic vessel coverage varies by age and size in adult zebrafish, this introduces additional variability in the assay that should be considered when planning experiments using this technique².

The specific uptake of fluorescent tracers by the lymphatic system depends on the size of the tracers²¹. The particle sizes below 100 nm can easily be taken by lymphatic vessels²². The size of QD is <10 nm; therefore, it was observed that most of the QD are taken up by the lymphatic system within 24 h post intramyocardial injection. It is unknown what immune response injected fluorescence tracers induce and how long this persists in zebrafish. However, previous studies in mice have shown that injected empty/blank MS do not induce a significant immune response²³^,²⁴, and typical survival from the procedure is 100% in adult zebrafish.

The intramyocardial injection has been used both clinically and experimentally in mammalian models to test or improve heart function after myocardial infarction with intramyocardial injection of stem and progenitor cells or exogenous compounds such as hydrogel⁸^,⁹^,¹⁰. Recently, MS has attracted great attention in the field of drug delivery and regeneration²⁵. We have demonstrated that myocardial injection of MS in zebrafish is possible and stable for over 3 weeks after injection. Furthermore, our preliminary data suggest that this method may be used to deliver exogenous compounds to the zebrafish heart. It will be interesting to apply this protocol to use functional MS to introduce exogenous compounds and cells to the zebrafish heart with broad applications across many areas of study.

Disclosures

The authors have nothing to disclose.

Acknowledgements

We thank Adedeji Afolalu, Chaim Shapiro, Soji Hosten, and Chelsea Quaies for fish care (Weill Cornell Medicine), Caroline Pearson (Weill Cornell Medicine) for critical reading of the manuscript. Jingli Cao (Weill Cornell Medicine) for use of dissection scope and camera to record the procedure in addition to critical reading of the manuscript. Nathan Lawson (University of Massachusetts Medical School), Brant Weinstein (NICHD), Elke Ober (University of Copenhagen), and Stephan Schulte-Merker (WWU Münster) for transgenic zebrafish lines. Daniel Castranova (NICHD) for advice on QD and imaging and Yu Xia (Weill Cornell Medicine) for guidance on dissecting scope video capture. This work was supported by a NYSTEM Fellowship to NM, American Heart Association Career Development Award (AHA941434), National Institutes of Health (NIH) grant (R01NS126209), and Weill Cornell Medicine Startup Fund to MH.

Materials

Crystallization dish	VWR	89000-288
Dissection Scope	Zeiss	495010-0007-000
Fish facility water	N/A	N/A	RO water with sea salt and sodium bicarbonate added to a conductivity of 226uS and pH of 7.35
Forceps	Dumont	11252-20
Glass Capillaries	WPI	1B120-3	no filament
ImageJ			https://imagej.nih.gov/ij/download.html
Iridectomy scissors	Fine Scientific Tools	15000-00
Microinjector	Warner Instruments	64-1735
Microloader femtotips	Eppendorf	5242 956.003
Micropipette puller	Sutter Instrument	P-97	Gated pedal input
Microspheres	Thermo Fisher Scientific	B200	Blue
PBS	Corning	46-013-CM
Quantum dots (QD)	Thermo Fisher Scientific	Q21061MP	Qtracker705 vascular label
Sponge	any	any	(1.5 × 5 × 3 cm) with groove (0.5 × 2.5 cm)
Syringe filter	Corning	431220
Tricaine	Sigma-Aldrich	A5040	concentration: 4 mg/mL

References

Munn, L. L., Padera, T. P. Imaging the lymphatic system. Microvascular Research. , 55 (2014).
Harrison, M. R., et al. Late developing cardiac lymphatic vasculature supports adult zebrafish heart function and regeneration. eLife. 8, 42762 (2019).
Gancz, D., et al. Distinct origins and molecular mechanisms contribute to lymphatic formation during cardiac growth and regeneration. eLife. 8, 44153 (2019).
Vivien, C. J., et al. Vegfc/d-dependent regulation of the lymphatic vasculature during cardiac regeneration is influenced by injury context. NPJ Regenerative Medicine. 4, 18 (2019).
Cueni, L. N., Detmar, M. The lymphatic system in health and disease. Lymphatic Research and Biology. 6 (3-4), 109 (2008).
Schwartz, N., et al. Lymphatic function in autoimmune diseases. Frontiers in Immunology. 10, 519 (2019).
Feng, X., Travisano, S., Pearson, C. A., Lien, C. L., Harrison, M. R. M. The lymphatic system in zebrafish heart development, regeneration and disease modeling. Journal of Cardiovascular Development and Disease. 8 (2), 1-14 (2021).
McCall, F. C., et al. Myocardial infarction and intramyocardial injection models in swine. Nature Protocols. 7 (8), 1479 (2012).
Williams, A. R., et al. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: Functional recovery and reverse remodeling. Circulation Research. 108 (7), 792-796 (2011).
Rodell, C. B., et al. Injectable shear-thinning hydrogels for minimally invasive delivery to infarcted myocardium to limit left ventricular remodeling. Circulation: Cardiovascular Interventions. 9 (10), 004058 (2016).
Bise, T., Jaźwińska, A. Intrathoracic injection for the study of adult zebrafish heart. Journal of Visualized Experiments. (147), e59724 (2019).
Konantz, J., Antos, C. L. Reverse genetic morpholino approach using cardiac ventricular injection to transfect multiple difficult-to-target tissues in the zebrafish larva. Journal of Visualized Experiments. (88), e51595 (2014).
Wagner, A. M., Knipe, J. M., Orive, G., Peppas, N. A. Quantum dots in biomedical applications. Acta Biomaterialia. 94, 44 (2019).
Rizvi, S. B., Ghaderi, S., Keshtgar, M., Seifalian, A. M. Semiconductor quantum dots as fluorescent probes for in vitro and in vivo bio-molecular and cellular imaging. Nano Reviews. 1 (1), 5161 (2010).
Van Nguyen, T., et al. Size determination of polystyrene sub-microspheres using transmission spectroscopy. Applied Sciences. 10 (15), 5232 (2020).
Harrison, M. R. M., et al. Chemokine-guided angiogenesis directs coronary vasculature formation in zebrafish. Developmental Cell. 33 (4), 442-454 (2015).
Gupta, V., et al. An injury-responsive gata4 program shapes the zebrafish cardiac ventricle. Current Biology. 23 (13), 1221-1227 (2013).
El-Sammak, H., et al. A Vegfc-Emilin2a-Cxcl8a signaling axis required for zebrafish cardiac regeneration. Circulation Research. 130 (7), 1014-1029 (2022).
Harris, N. R., et al. VE-Cadherin is required for cardiac lymphatic maintenance and signaling. Circulation Research. 130 (1), 5-23 (2022).
Henri, O., et al. Selective stimulation of cardiac lymphangiogenesis reduces myocardial edema and fibrosis leading to improved cardiac function following myocardial infarction. Circulation. 133 (15), 1484-1497 (2016).
Rao, D. A., Forrest, M. L., Alani, A. W. G., Kwon, G. S., Robinson, J. R. Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery. Journal of Pharmaceutical Sciences. 99 (4), 2018-2031 (2010).
Casley-Smith, J. R. The fine structure and functioning of tissue channels and lymphatics. Lymphology. 13 (4), (1980).
Liu, Y., et al. Experimental vaccine induces Th1-driven immune responses and resistance to Neisseria gonorrhoeae infection in a murine model. Mucosal Immunology. 10, 1594-1608 (2017).
Wang, D., et al. Poly(D,L-Lactic-co-Glycolic Acid) microsphere delivery of adenovirus for vaccination. Journal of Pharmaceutical Sciences. 10 (2), 217-230 (2007).
Li, Q., Chang, B., Dong, H., Liu, X. Functional microspheres for tissue regeneration. Bioactive Materials. , (2022).

Automatically Generated